CytoLynx Therapeutics

Leading the application of iNK cell therapy, and multi-specific Antibody NK Engager in cancer immunotherapy and harnessing the potential of iPSC to revolutionize cancer immunotherapy towards a cure.

CytoLynx Therapeutics

Leading the application of iNK cell therapy, and multi-specific Antibody NK Engager in cancer immunotherapy and harnessing the potential of iPSC to revolutionize cancer immunotherapy towards a cure.

Our Mission

 

Based on the Nobel Prize winning iPSC technology, Cytolynx Thereapeutics is developing the cutting edge iPSC derived cell threpeutics, bringing more efficient and affordable treatments to benefit patients worldwide.

About Us

 

CytoLynx Therapeutics is an iPSC-NK cell therapy company founded in July 2021 with fully charged innovation focusing on cell therapy and antibody therapy and having discovery, development, GMP manufacturing and clinical trials in greater China and Global market. 

MORE